Prognostic Impact of Postoperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer
- 24 August 2011
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 19 (2) , 636-641
Abstract
Background Perioperative serum carbohydrate antigen 19-9 (CA 19-9) level has been reported to be a useful prognostic marker in pancreatic cancer. The object of this study was to investigate the...Keywords
This publication has 18 references indexed in Scilit:
- Adjuvant therapy and survival after resection of pancreatic adenocarcinomaCancer, 2010
- Adjuvant and Neoadjuvant Therapy in Curable Pancreatic CancerSurgical Clinics of North America, 2010
- Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704Journal of Clinical Oncology, 2008
- Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005)Journal of Clinical Oncology, 2008
- Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic AdenocarcinomaAnnals of Surgery, 2007
- The Use of Adjusted Preoperative CA 19-9 to Predict the Recurrence of Resectable Pancreatic CancerJournal of Surgical Research, 2007
- Clinical Implications of Combined Portal Vein Resection as a Palliative Procedure in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Head CarcinomaAnnals of Surgical Oncology, 2006
- Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tailSurgery, 2006
- Prognostic Nomogram for Patients Undergoing Resection for Adenocarcinoma of the PancreasAnnals of Surgery, 2004
- Undetectable Preoperative Levels of Serum CA 19-9 Correlate with Improved Survival for Patients with Resectable Pancreatic AdenocarcinomaAnnals of Surgical Oncology, 2004